| Today’s Big NewsFeb 23, 2024 |
| By Nick Paul Taylor GSK is walking away from a core piece of its $345 million bet on Vir Biotechnology. The partners have ended their collaboration on anti-influenza antibodies, freeing Vir to “actively” pitch the candidates to other companies while continuing to work with GSK on different respiratory pathogens. |
|
|
|
By James Waldron Galapagos used its earnings report to disclose that work has been halted on a CD19 CAR-T candidate for refractory systemic lupus erythematosus. |
By Max Bayer Frontier Medicines has just closed a $80 million fundraising, but, according to CEO Chris Varma, Ph.D., corralling the capital was, in his own words, harder than the bleakest days of the Great Recession. |
Sponsored by Datapharm What gains can pharma and healthcare sectors make from adopting digital medicines information standards, and how can they prepare for the transition? |
By Max Bayer,Gabrielle Masson AbbVie has formally announced that President and COO Robert Michael will succeed Rick Gonzalez as CEO. |
By Helen Floersh A drug with past life as a potential anti-cancer agent might someday have a new job as a reversible contraceptive for men, new data in mice suggest. |
By Ayla Ellison,Fraiser Kansteiner This week on "The Top Line," we explore the impact of environmental, social, and governance measures, commonly known as ESG, on the pharmaceutical industry. Fierce Pharma's Fraiser Kansteiner engages in a conversation with Jim Greffet, Head of ESG Strategy at Eli Lilly, to gain insights and discuss Lilly's specific ESG initiatives. |
By Fraiser Kansteiner As the Biden administration’s exploration of “march-in rights" draws support from powerful entities like the Federal Trade Commission, a small group of lawmakers on both sides of the aisle have warned the approach could “hamstring” U.S. innovation. |
By Helen Floersh Munich-based FGK Clinical Research has acquired Clinicology Ltd., a U.K.-based contract research organization. |
By Angus Liu Even Alexnder Hardy, the former Genentech leader who managed the blockbuster hemophilia drug Hemlibra, can’t immediately bend the laggard launch trajectory of BioMarin’s gene therapy Roctavian. |
By Angus Liu Daiichi Sankyo is investing 1 billion euros to expand its German site. Astellas partnered with Kelonia on cell therapy tech. Novartis launched a strategic review of a subsidiary in India that's focused on older meds. And more. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we explore the impact of environmental, social, and governance measures, commonly known as ESG, on the pharmaceutical industry. Fierce Pharma's Fraiser Kansteiner engages in a conversation with Jim Greffet, Head of ESG Strategy at Eli Lilly, to gain insights and discuss Lilly's specific ESG initiatives. |
|
|---|
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
